We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Stellar Biotechnologies, Inc. (MM) | NASDAQ:SBOT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.05 | 1.06 | 1.08 | 0 | 01:00:00 |
British Columbia, Canada
|
|
001-37619
|
|
N/A
|
(State
or Other Jurisdiction of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
|
|
|||
100 Spy Court
Markham, Ontario, Canada L3R 5H6
|
||||
(Address
of Principal Executive Offices)
|
Title
of each class
|
Trading
Symbol(s)
|
Name of
exchange on which registered
|
Common
Shares
|
EDSA
|
The
Nasdaq Capital Market
|
ExhibitNo.
|
|
Description of Exhibit
|
|
|
|
2.1
+
|
|
Share
Exchange Agreement, dated as of March 7, 2019, by and between
Stellar Biotechnologies Inc., Edesa Biotech Inc. and the Edesa
Shareholders (incorporated by reference to Exhibit 2.1 to the
Company’s Current Report on Form 8-K filed with the
Securities and Exchange Commission on March 8, 2019).
|
|
|
|
3.1
+
|
|
Certificate
of Amendment to the Restated Certificate of Incorporation of the
Company, dated June 7, 2019.
|
|
|
|
10.1
*+
|
|
Employment
Agreement, dated as of June 7, 2019, by and between the Registrant
and
Kathi
Niffenegger
.
|
|
|
|
10.2
*+
|
|
Employment
Agreement, dated as of June 14, 2019, by and between the Registrant
and
Dr. Pardeep
Nijhawan
.
|
|
|
|
10.3
*+
|
|
Employment
Agreement, dated as of June 14, 2019, by and between the Registrant
and
Michael
Brooks
.
|
10.4
*+
|
|
Form of
Indemnification Agreement, by and between the Company and each of
its directors and executive officers.
|
|
|
|
16.1
+
|
|
Letter
from Moss Adams, LLP dated June 7, 2019.
|
|
|
|
|
Consent
of MNP LLP, independent registered public accounting firm,
regarding the audited financial statements of Edesa Biotech,
Inc.
|
|
|
|
|
99.1
+
|
|
Press
Release dated June 7, 2019.
|
|
|
|
|
Audited
financial statements of Edesa Biotech Inc. as of and for the years
ended December 31, 2018 and 2017.
|
|
|
|
|
|
Unaudited
condensed interim financial statements of Edesa Biotech Inc. as of
March 31, 2019 and for the three months ended March 31, 2019 and
2018.
|
|
|
|
|
|
Unaudited
Pro Forma Condensed Combined Financial Statements for the year
ended December 31, 2018 (incorporated by reference to the
Company's Definitive Proxy Statement on Schedule
DEFM14A filed with the Securities and Exchange Commission on April
18, 2019).
|
|
|
|
|
|
Unaudited
Pro Forma Condensed Combined Financial Statements for the three
months ended March 31, 2019.
|
|
EDESA
BIOTECH, INC.
|
|
|
|
|
|
|
Date:
August 14,
2019
|
By:
|
/s/
Kathi
Niffenegger
|
|
|
Name:
|
Kathi
Niffenegger
|
|
|
Title:
|
Chief Financial
Officer
|
|
1 Year Stellar Biotechnologies Inc. Chart |
1 Month Stellar Biotechnologies Inc. Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions